PURPOSE: In a recent meta-analysis of 38 double-blind randomized controlled trials (RCTs) comparing @entity4481 ( @entity11974 ) to placebo, we found 20 adverse events (AEs) to be significantly associated with @entity11974 treatment. In the present study, we evaluated whether the incidence of these 20 AEs differs across distinct disorders in which @entity11974 was investigated. METHODS: Among the 38 previously identified RCTs of @entity11974 , we selected only those including a @entity11974 600  mg/day arm and subsequently classified them into four distinct groups according to the disorder in which @entity11974 was investigated: (1) drug-resistant partial @entity302 , (2) @entity146 , (3) @entity239 , and (4) @entity9 . We used risk differences (RDs) to quantify the placebo-corrected proportion of subjects discontinuing @entity11974 due to intolerable AEs and to determine the placebo-corrected incidence of each of the 20 @entity11974 AEs across the four disorders. RESULTS: Twenty-two RCTs were included in this study. Neither the proportion of subjects discontinuing @entity11974 due to intolerable AEs nor the incidence of @entity11974 AEs (with the exception of @entity2055 ) differed significantly across the four disorders. @entity2055 was more common in drug-resistant partial @entity302 compared to @entity239 . When limiting analyses to subjects on placebo, most @entity76 ( @entity2055 , @entity892 , and @entity227 ) were found to be more common in drug-resistant partial @entity302 compared to all other disorders. @entity227 were more common in @entity302 than in @entity9 ; and @entity2055 had a higher incidence in @entity302 than in @entity148 and @entity239 . Among other CNS AEs, @entity2147 was more common in @entity302 compared to @entity9 and in @entity148 alone compared to @entity9 and @entity239 . Asthenia was also more common in @entity302 than in @entity9 and @entity239 . CONCLUSIONS: Although drug-resistant partial @entity302 is associated with a higher probability of developing @entity76 , the risk for @entity11974 @entity137 does not differ across distinct disorders.

The adverse event profile of XXXX across different disorders: a meta-analysis.

@entity227 :: ('MESH:D014786', 'Disease') :: ['Diplopia and blurred vision', 'blurred vision'] @entity239 :: ('MESH:D005356', 'Disease') :: ['fibromyalgia'] @entity11974 :: ('MESH:D011456', 'Chemical') :: ['PGB'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders'] @entity2147 :: ('MESH:D006970', 'Disease') :: ['somnolence'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety disorder', 'anxiety disorders'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy'] @entity76 :: ('MESH:D002526', 'Disease') :: ['vestibulo-cerebellar AEs'] @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia'] @entity4481 :: ('MESH:C080245', 'Chemical') :: ['pregabalin'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain'] @entity2055 :: ('MESH:D001259', 'Disease') :: ['ataxia', 'Ataxia']
@entity4481 :: (MESH:C080245,Chemical) :: ['pregabalin']
